|
ADAMTS13
|
Ischemic stroke
|
0.190 |
GeneticVariation |
BEFREE |
We describe a case of cTTP first diagnosed at age 70 years in a female presenting with an acute ischaemic stroke and thrombocytopenia, in whom A Disintegrin And Metalloproteinase with a Thrombospondin type 1 Motif, member 13 (ADAMTS13) levels were <10%, suggestive of thrombotic thrombocytopaenic purpura (TTP).
|
31585956 |
2019 |
|
ADAMTS13
|
Ischemic stroke
|
0.190 |
Biomarker |
BEFREE |
Based on research findings from <i>in vitro</i>, animal, and clinical studies, we propose that ADAMTS13 is a potential biomarker to guide appropriate treatment for ischemic stroke and a promising therapeutic agent for tPA resistant thrombi.
|
31379722 |
2019 |
|
ADAMTS13
|
Ischemic stroke
|
0.190 |
Biomarker |
BEFREE |
Prophylactic ADAMTS13 replacement decreases the risk of end-organ damage such as ischemic stroke and resolved previously unrecognized symptoms in patients with nonovert disease.
|
30770395 |
2019 |
|
ADAMTS13
|
Ischemic stroke
|
0.190 |
Biomarker |
BEFREE |
Our understanding of the pathophysiology of TTP has allowed us to grasp the important role of ADAMTS13 in other thrombotic microangiopathies (TMAs) and thrombotic disorders, such as ischemic stroke and coronary artery disease.
|
30006329 |
2018 |
|
ADAMTS13
|
Ischemic stroke
|
0.190 |
GeneticVariation |
BEFREE |
In contrast, low ADAMTS13 was associated with increased risk of dementia throughout follow-up (hazard ratio per SD decrease- 1.16 [1.06-1.28]), which alike for ischaemic stroke, was modified by the presence of diabetes (P-interaction = 0.003).
|
29615758 |
2018 |
|
ADAMTS13
|
Ischemic stroke
|
0.190 |
Biomarker |
BEFREE |
This study aimed to determine a possible association of mediators of inflammation and haemostasis (C-reactive protein, interleukin-6, matrix metalloproteinase-9, monocyte chemoattractant protein-1, asymmetric dimethylarginine [ADMA], symmetric dimethylarginine, von Willebrand factor and a disintegrin and metalloproteinase with a thrombospondin type 1 motif 13 [ADAMTS-13]) with the post-intervention grade of reperfusion, complications and clinical outcome in patients who underwent endovascular treatment of ischaemic stroke.
|
29618156 |
2018 |
|
ADAMTS13
|
Ischemic stroke
|
0.190 |
GeneticVariation |
GWASCAT |
Genetic Drivers of von Willebrand Factor Levels in an Ischemic Stroke Population and Association With Risk for Recurrent Stroke.
|
28495826 |
2017 |
|
ADAMTS13
|
Ischemic stroke
|
0.190 |
AlteredExpression |
BEFREE |
Therefore, the aim of this study was to compare plasma levels of ADAMTS13 between 85 healthy volunteers (HV), 104 patients with acute ischemic stroke and 112 patients with a chronic cerebrovascular disease (CCD).
|
28591212 |
2017 |
|
ADAMTS13
|
Ischemic stroke
|
0.190 |
Biomarker |
BEFREE |
Role of reduced ADAMTS13 in arterial ischemic stroke: a pediatric cohort study.
|
23225307 |
2013 |
|
ADAMTS13
|
Ischemic stroke
|
0.190 |
GeneticVariation |
BEFREE |
High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability.
|
16990571 |
2006 |